Treatment solutions for numerous diseases that combine therapies and diagnosis are referred to as theragnosis. Theragnosis is a new concept in next-generation medicine that integrates diagnosis and treatment at the same time. Theragnostic nanoparticles (NPs) combine diagnostic and therapeutic activities into a single integrated system, allowing for simultaneous diagnosis, therapy, and therapeutic response monitoring. Noninvasive imaging methods must be included in theragnostic NPs' diagnostic function. Theragnostic encompasses a wide range of issues, including personalised medicine, pharmacogenomics, and molecular imaging, to produce efficient new targeted medicines with acceptable benefit/risk to patients and a deeper molecular understanding of how to optimise medication selection. For successful theragnosis applications, imaging agents and drugs must be given efficiently, resulting in suitable imaging signal or drug concentration in the specific disease area.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States